News

The primary endpoint in the double-blind safety study is evaluation of blood pressure effects of subcutaneous Bremelanotide in men between 45 and 65 years old. The study is

Denosumab demonstrated superiority over Zometa for both delaying the time to the first on-study skeletal related event (fracture, radiation to bone, surgery to bone or spinal cord compression)

Takeda has been evaluating all published data and communications from the FDA regarding the potential risks associated with concomitant use of clopidogrel and PPIs. The clinical trial, titled

As per the agreement, Novartis will make an upfront payment to Debiopharm, and the latter will be eligible for milestone payments and royalties on future sales of Debio

The trial was based on age (men= 50 and women= 60), high-sensitivity C-reactive protein (hsCRP) = 2mg/l, and the presence of at least one additional CVD risk factor,

Ligon is expected to apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Patrick Kleyn, CEO of

The approval for Prezista was based on data from the Delphi trial. In the open-label, Phase 2 trial, the pharmacokinetics, safety, tolerability and efficacy of Prezista dosed twice

The FDA indicated that it intends to reschedule the meeting as soon as it can determine a schedule that will allow them to reconvene the advisory panel. This

LIPO-102 is a new, minimally-invasive, non-ablative approach to localised fat reduction comprising an injectable aqueous combination of salmeterol xinafoate (SX) and fluticasone propionate (FP). Reportedly, the Phase I